Several targeted medicines, such as FLT3 inhibitors, IDH1/2 inhibitors, and BCL-2 inhibitor Venetoclax, as well as biotherapeutics (e.g., antibody-drug conjugates) for AML therapy have been developed and approved by the FDA over the last 10 years [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. Here, FLT3 is linked to acute myeloid leukemia.